Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Trials|November 4, 2015
Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trialKaren M Savage, Con K Stough, Gerard J Byrne, et al.
Translational Psychiatry|August 28, 2025
Advancing paroxetine treatment in depression: predicting remission and plasma concentration, and validating and updating therapeutic reference rangesRui Yuan, Yundan Liao, Xuan Lu, et al.
The American Journal of Psychiatry|December 7, 2016
Accelerated Gray and White Matter Deterioration With Age in SchizophreniaVanessa L Cropley, Paul Klauser, Rhoshel K Lenroot, et al.
European Journal of Nutrition|September 27, 2019
EPA and DHA as markers of nutraceutical treatment response in major depressive disorderKiki P van der Burg, Lachlan Cribb, Joseph Firth, et al.
Schizophrenia Bulletin|October 6, 2017
Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive AbilitiesTamsyn E Van Rheenen, Vanessa Cropley, Andrew Zalesky, et al.
Journal of Psychiatry & Neuroscience : JPN|October 31, 2025
Differential DNA methylation and gene expression in stem cell-derived cardiomyocytes from patients with and without a history of clozapine-induced myocarditisDiogo F Marques, Leticia M Spindola, Ankita Narang, et al.
NPJ Schizophrenia|June 24, 2016
The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomesRuth Wells, Vaidy Swaminathan, Suresh Sundram, et al.
Schizophrenia Bulletin|May 4, 2019
The Impact of Childhood Adversity on Cognitive Development in SchizophreniaRuth Wells, Isabella Jacomb, Vaidy Swaminathan, et al.
Molecular Psychiatry|February 8, 2023
Perturbed iron biology in the prefrontal cortex of people with schizophreniaAmit Lotan, Sandra Luza, Carlos M Opazo, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2018
Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial<sup/>Jerome Sarris, Gerard J Byrne, Chad Bousman, et al.
Pageof 7